HGH Fragment 176-191 Pharmaceutical Raw Materials AOD 9604 221231-10-3

HGH Fragment 176-191 Pharmaceutical Raw Materials AOD 9604 221231-10-3

Specification:

Specification:(2mg/vial,10vial/box or 5mg/vial,10vial/box)

Description :

Fragment (176-191) is a fat-loss peptide derived from the GH molecule, which directly initiates lipolysis and inhibits lipogenesis, but in order to better understand this peptide, it is imperative to have at least a rudimentary understanding of its parent hormone .

GH is a polypeptide which contains an amino acid sequence that is 191 amino acids in length. Frag (176-191) was developed by isolating and modifying the specific portion of the GH molecule responsible for the hormone's lipolytic and anti-lipogenic effects.

The portion of the molecule responsible for these effects is amino acids 176-191. In every sense, Frag should primarily be considered a fat loss peptide which performs these functions through the same pathways as traditional GH, but without exposing the user to the potentially undesirable side effects which may present themselves during GH administration.

Application :
the GH fragment 176-191 stimulates lipolysis and inhibits lipogenesis both en vivo/en vitro.
Fragment 176191 has shown no effect on growth or insulin resistance, unlike the full GH molecule. This is the newest, most powerful GH fragment on the market. Studies have shown sustained fatloss, aimed directly at adipose tissue.

It has been shown that the fat-reducing effects of GH appear to be controlled by a small analog region of the C-terminus end of the GH molecule. This region consists of amino acids 176-191, thus the name. This peptide fragment works by mimicking the way natural hGH regulates fat metabolism but without the adverse effects on blood sugar that is seen with unmodified hGH.